Melanoma as a model for precision medicine in oncology
Mené sur 675 patients atteints d'un mélanome métastatique (104 centres hospitaliers, 12 pays), cet essai de phase III compare, du point de vue de la survie globale et de la survie sans progression, le vemurafenib et la dacarbazine en fonction de la présence de mutations V600E ou V600K du gène BRAF (durée médiane de suivi pour le vemurafenib : 12,5 mois; pour la dacarbazine : 9,5 mois)
Advances in the understanding of the molecular profile of tumour cells and progress in systems biology and bioinformatics have led to the promise of precision medicine for treatment of human cancer. Melanoma has provided an opportunity for insights into both the potential benefit and limitations of precision medicine for cancer.
In 2002, half of all human melanoma cells were shown to harbour mutations in the BRAF gene, the product of which has an important role in cell division, differentiation, an ...
The Lancet Oncology , commentaire, 2013